指南与共识支持与姑息治疗

德国血液与肿瘤内科学会感染病工作组:癌症患者抗感染疫苗接种策略更新指南

Anti-infective vaccination strategies in patients with haematological malignancies or solid tumours: updated guideline of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology.
指南 / 共识 · Lancet Oncol · 2026-01-01

该更新指南由德国血液与肿瘤内科学会感染病工作组制定,专家组涵盖内科、血液科、肿瘤内科和感染病学。指南针对既往已涵盖的疫苗纳入了2017年起癌症患者的所有文献,对新纳入疫苗则回顾所有文献,经数据提取和批判性讨论后按国际标准化分级系统给出推荐。更新引入一般性推荐、最佳接种时机、减毒活疫苗的潜在使用及密切接触者和家庭成员的免疫接种,并新增实体瘤和血液系统恶性肿瘤专节及接受酪氨酸激酶抑制剂、双特异性抗体和嵌合抗原受体T细胞等新疗法患者的指导。

要点

  • 疫苗可预防感染仍是癌症患者发病和死亡的主要原因,指南旨在提高接种率。
  • 更新引入一般推荐、最佳接种时机、减毒活疫苗使用及密切接触者免疫接种。
  • 新增实体瘤与血液肿瘤专节,并覆盖TKI、双特异性抗体和CAR-T治疗患者。

核心结论

  • 指南针对癌症患者抗感染疫苗接种策略给出更新推荐,旨在减少疫苗可预防疾病并提高患者及照护者的接种率。

研究设计与样本

  • 由德国血液与肿瘤内科学会感染病工作组组织内科、血液科、肿瘤内科和感染病学专家制定更新指南。
  • 对既往已涵盖的疫苗纳入2017年起癌症患者的所有文献,对新纳入疫苗回顾所有文献,经数据提取和批判性讨论后按国际标准化分级系统分级推荐。

主要发现

  • 更新引入一般性推荐、最佳接种时机、减毒活疫苗的潜在使用以及密切接触者和家庭成员的免疫接种。
  • 新增实体瘤患者和血液系统恶性肿瘤患者的专节。
  • 增加接受酪氨酸激酶抑制剂、双特异性抗体和嵌合抗原受体T细胞等新疗法患者的指导。

临床怎么用

  • 肿瘤内科医生应参照该更新指南为实体瘤和血液肿瘤患者制定抗感染疫苗接种策略。
  • 对接受TKI、双特异性抗体或CAR-T等新疗法的患者,应按指南新增指导评估疫苗接种。
  • 应关注患者密切接触者和家庭成员的免疫接种以降低疫苗可预防感染风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccine-preventable infections remain a major cause of morbidity and mortality in patients with cancer. The updated guideline for anti-infective vaccination strategies in patients with cancer of the German Society of Hematology and Medical Oncology Infectious Diseases Working Group was developed by a guideline panel of experts in internal medicine, haematology, medical oncology, and infectious diseases. For previously covered vaccinations, we included all publications in patients with cancer starting from 2017, as this was the data cutoff for the previous guideline, and for newly included vaccines all publications were reviewed. After data extraction and critical discussion, the recommendations were graded following a standardised international grading system. This update introduces general recommendations, optimal vaccination timing, potential use of live vaccines, and immunisation of close contacts and household members of patients. Moreover, specific sections for patients with solid tumours and patients with haematological malignancies have been introduced. Guidance has been added for patients receiving novel therapies such as tyrosine kinase inhibitors, bispecific antibodies, and chimeric antigen receptor T cells. This guideline addresses the urgent medical need to reduce vaccine-preventable diseases and aims to improve vaccination uptake among patients with cancer and their caregivers.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Mellinghoff SC, Liss B, Stemler J, et al. Anti-infective vaccination strategies in patients with haematological malignancies or solid tumours: updated guideline of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology. Lancet Oncol. 2026. PMID: 41926972. doi:10.1016/S1470-2045(25)00765-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。